हमारा समूह 1000 से अधिक वैज्ञानिक सोसायटी के सहयोग से हर साल संयुक्त राज्य अमेरिका, यूरोप और एशिया में 3000+ वैश्विक सम्मेलन श्रृंखला कार्यक्रम आयोजित करता है और 700+ ओपन एक्सेस जर्नल प्रकाशित करता है जिसमें 50000 से अधिक प्रतिष्ठित व्यक्तित्व, प्रतिष्ठित वैज्ञानिक संपादकीय बोर्ड के सदस्यों के रूप में शामिल होते हैं।
ओपन एक्सेस जर्नल्स को अधिक पाठक और उद्धरण मिल रहे हैं
700 जर्नल और 15,000,000 पाठक प्रत्येक जर्नल को 25,000+ पाठक मिल रहे हैं
Teesha Arora and David Wright
Lemierre’s syndrome (postanginal septicaemia/human necrobacillosis) was first defined and described in 1936 by Lemierre, a French Physician and Professor in Microbiology, although the first case report of human necrobacillosis was published in 1900 by Courmont and Cade [1,2]. Lemierre’s syndrome has come to be known as the “forgotten” disease, as very few cases have been reported since the introduction and widespread use of antibiotics [3,4]. In the preantibiotic era, Lemierre’s Syndrome was associated with a mortality rate of approximately 90% [1]. Currently, the associated mortality rate is estimated to range from 5% to 10% [5-7]. Since 1974, less than 100 cases have been reported [8,9]. This can be explained by the fact that more throat infections received early treatment with the widespread use of antibiotics, leading to the decrease in the incidence of Lemierre’s disease. The syndrome is characterised by a recent history of oropharyngitis with persistent fevers, followed by septic thrombophlebitis of the internal jugular vein and dissemination of the infection to multiple sites distant to the pharynx [10]. Fusobacterium species are responsible in most cases. It affects previously healthy adolescents and young adults.